Late-breaking data from Phase 3 investigational study presented at the American College of Rheumatology Convergence show 58% of ICOTYDE-treated patients achieved an ACR20 response and 29% achieved an ACR50 response at Week 16 ICOTYDE is a first-in-class IL-23R targeted oral peptide,...
Hence then, the article about johnson johnson announces icotyde icotrokinra delivers significant improvement in psoriatic arthritis disease activity among biologic naive patients with once daily targeted oral peptide was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Johnson & Johnson announces ICOTYDE® (icotrokinra) delivers significant improvement in psoriatic arthritis disease activity among biologic-naive patients with once-daily targeted oral peptide )
Also on site :
- Dortmund Host Elversberg in Crucial Bundesliga Clash as Title Race Heats Up
- A ‘geologic freak’ called the Smackover may end America’s lithium dependence on China, and Big Oil is already there
- ‘Triplets of Belleville’ Director Sylvain Chomet Fires Back at AI Accusations Over Dior Film Featuring Robert Pattinson’s Voice: ‘Everything Was Drawn by Hand’ (EXCLUSIVE)